This study tests a new drug combination (vusolimogene oderparepvec plus pembrolizumab) in 18 adults with advanced angiosarcoma, a rare cancer of blood vessels. Participants must have already tried immunotherapy without success. The goal is to see if the treatment is safe and can …
Phase: PHASE2 • Sponsor: Varun Monga, MBBS • Aim: Disease control
Last updated May 15, 2026 11:53 UTC